Association of COVID-19 with comorbidities: An update
S Chatterjee, LV Nalla, M Sharma… - ACS Pharmacology & …, 2023 - ACS Publications
Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome-
coronavirus-2 (SARS-CoV-2) which was identified in Wuhan, China in December 2019 and …
coronavirus-2 (SARS-CoV-2) which was identified in Wuhan, China in December 2019 and …
Comorbidities and clinical complications associated with SARS-CoV-2 infection: an overview
A Gupta, H Marzook, F Ahmad - Clinical and experimental medicine, 2023 - Springer
The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes major
challenges to the healthcare system. SARS-CoV-2 infection leads to millions of deaths …
challenges to the healthcare system. SARS-CoV-2 infection leads to millions of deaths …
[HTML][HTML] COVID-19 and comorbidities: Deleterious impact on infected patients
The pandemic situation with the emergence of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) from China has endangered human lives. Coronavirus …
coronavirus 2 (SARS-CoV-2) from China has endangered human lives. Coronavirus …
Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: a pathway-based analytical study
R Parit, S Jayavel - European journal of pharmacology, 2021 - Elsevier
Abstract Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) outbreak is a
major public health concern, which has accounted for> 1.7 million deaths across the world …
major public health concern, which has accounted for> 1.7 million deaths across the world …
Interrelations between COVID-19 and other disorders
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a respiratory tract
virus that causes Coronavirus disease (COVID-19). The virus originated in Wuhan, China, in …
virus that causes Coronavirus disease (COVID-19). The virus originated in Wuhan, China, in …
Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors
T Yin, Y Li, Y Ying, Z Luo - BMC infectious diseases, 2021 - Springer
Abstract Background Coronavirus disease 2019 (COVID-19) is an infectious disease
characterized by cough, fever, and fatigue and 20% of cases will develop into severe …
characterized by cough, fever, and fatigue and 20% of cases will develop into severe …
Comorbidity and its impact on patients with COVID-19
A Sanyaolu, C Okorie, A Marinkovic, R Patidar… - SN comprehensive …, 2020 - Springer
A novel human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), was identified in Wuhan, China, in December 2019. Since then, the virus has made its …
2), was identified in Wuhan, China, in December 2019. Since then, the virus has made its …
Comorbidities of COVID-19 patients
R Silaghi-Dumitrescu, I Patrascu, M Lehene, I Bercea - Medicina, 2023 - mdpi.com
The novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) responsible
for the coronavirus disease outbreak initiated in 2019 (COVID-19) has been shown to affect …
for the coronavirus disease outbreak initiated in 2019 (COVID-19) has been shown to affect …
Impact of comorbidities on patients with COVID‐19: A large retrospective study in Zhejiang, China
C Ye, S Zhang, X Zhang, H Cai, J Gu… - Journal of medical …, 2020 - Wiley Online Library
Abstract Coronavirus disease 2019 (COVID‐19) has become a serious public health
problem worldwide. Here, we stratified COVID‐19 patients based on their comorbidities to …
problem worldwide. Here, we stratified COVID‐19 patients based on their comorbidities to …
COVID-19: in the eye of the cytokine storm
R De la Rica, M Borges, M Gonzalez-Freire - Frontiers in immunology, 2020 - frontiersin.org
The dysregulated release of cytokines has been identified as one of the key factors behind
poorer outcomes in COVID-19. This “cytokine storm” produces an excessive inflammatory …
poorer outcomes in COVID-19. This “cytokine storm” produces an excessive inflammatory …